BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Business

  Impax Laboratories Mourns the Passing of Board Member Richard A. Bierly

  Appointed in August 2016, Richard also served on the Board’s Audit and Compensation Committees.

  November 8, 2017

   · 

  6 min read
• Biotech Beach

  Regen BioPharma’s Chief Scientific Officer Explains the Link Between its NR2F6 Medicinal Chemistry and Three-Dimensional X-Ray Structure Programs

  The company recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor.

  November 8, 2017

   · 

  3 min read
• Important Tax Notice to U.S. Shareholders of Portage Biotech

  This statement is provided for shareholders who are United States persons for purposes of the U.S. Internal Revenue Code of 1986, as amended and the related United States Treasury regulations.

  November 8, 2017

   · 

  2 min read
• Business

  Alliar Announces 3Q17 Results

  Net revenue1 growth of 14.0% in Q3, with same store sales of 7%. YTD growth of 18.0%, SSS of 11%.

  November 8, 2017

   · 

  1 min read
• FDA

  Orthocell Receives CE Mark for CelGro

  CelGro, for a range of dental bone and soft tissue regeneration procedures, can now be marketed and sold within the European Union (EU).

  November 8, 2017

   · 

  4 min read
• 

  Business

  Boehringer, MiNA Therapeutics Forge EUR 307M R&D NASH Tie-Up

  Fresh off the heels of a $201M liver disease R&D deal with Dicerna, Boehringer Ingelheim has struck another deal targeting liver disease with MiNA Therapeutics.

  November 8, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Why Teva’s Stock Could Crash Another 50%

  Teva continues to be battered by its massive debt load and struggling pipeline.

  November 8, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Five Prime Tanked on Early Peek of Lead Drug Data

  Five Prime stock took a beating after it unintentionally released Phase Ia/Ib clinical trial of its CSF-1R antibody cabiralizumab with BMS’ Opdivo (nivolumab).

  November 8, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Genetown

  Cambridge’s Exonics Therapeutics Scores $40M

  Exonics Therapeutics closed on a $40M Series A financing which was led by The Column Group.

  November 8, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  Bay Area’s Tricida Closes $57.5M Series D, Pushes Into Phase III Trial

  Proceeds will be used to complete the ongoing pivotal TRCA-301 Phase 3 clinical trial of TRC101.

  November 8, 2017

   · 

  3 min read

   · 

  Mark Terry